Cyclo-oxygenase 2 Inhibitors Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 20+ Companies Working in the Domain
New York, USA, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Cyclo-oxygenase 2 Inhibitors Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 20+ Companies Working in the Domain
The Cyclooxygenase-2 (COX-2) inhibitors market is primarily driven by the increasing demand for effective pain management solutions due to the rising prevalence of chronic pain conditions and inflammatory diseases, coupled with the aging population that is more susceptible to arthritis and similar disorders. Advancements in drug development have expanded the therapeutic applications of COX-2 inhibitors, including potential roles in cancer prevention and treatment, while minimizing the gastrointestinal side effects typically associated with traditional NSAIDs.
DelveInsight’s 'Cyclo-oxygenase 2 Inhibitors Pipeline Insight 2024' report provides comprehensive global coverage of pipeline cyclo-oxygenase 2 inhibitors in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the cyclo-oxygenase 2 inhibitors pipeline domain.
Key Takeaways from the Cyclo-oxygenase 2 Inhibitors Pipeline Report
- DelveInsight’s cyclo-oxygenase 2 inhibitors pipeline report depicts a robust space with 20+ active players working to develop 20+ pipeline cyclo-oxygenase 2 inhibitors.
- Key cyclo-oxygenase 2 inhibitors companies such as Allodynic Therapeutics, Merck & Co., Axsome Therapeutics, Novilla Pharmaceuticals, Daehwa Pharmaceutical, Holy Stone Healthcare, NeuroSense Therapeutics, Virios Therapeutics, Sound Pharmaceuticals, Sirnaomics, Yiviva, and others are evaluating new cyclo-oxygenase 2 Inhibitors drugs to improve the treatment landscape.
- Promising pipeline cyclo-oxygenase 2 inhibitors such as CA102N, ALLOD 2, MK 0663, AXS 07, NOV-1776, DHP-2306, PrimeC, IMC-2, SPI-1005, STP 707, YIV 906, and others are under different phases of cyclo-oxygenase 2 inhibitors clinical trials.
- In July 2024, Sirnaomics had concluded the Phase I clinical trial of a small interfering RNA (siRNA) therapeutic candidate, STP707, to treat patients with pancreatic cancer.
- In April 2024, Axsome Therapeutics presented new pooled data from two Phase III trials, MOMENTUM (NCT0389600) and INTRCEPT (NCT04163185), evaluating AXS-07 (Molecular Solubility Enhanced Inclusion Complex [MoSEIC] meloxicam and rizatriptan) as an acute treatment for migraine in a poster session.
- In April 2024, Rakuten Medical announced a poster presentation of its study to manage edema following photoimmunotherapy with COX-2 Inhibition at the 115th Annual Meeting of the American Association for Cancer Research.
- In December 2023, NeuroSense’s announced Top-Line Results from 6-month double-blind Phase IIb PARADIGM trial with NeuroSense’s lead drug candidate for ALS, PrimeC.
Request a sample and discover the recent advances in cyclo-oxygenase 2 inhibitors drugs @ Cyclo-oxygenase 2 Inhibitors Pipeline Report
The cyclo-oxygenase 2 inhibitors pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage cyclo-oxygenase 2 inhibitors drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the cyclo-oxygenase 2 inhibitors clinical trial landscape.
Cyclo-oxygenase 2 Inhibitors Overview
Cyclo-oxygenase 2 (COX-2) inhibitors are a class of drugs designed to reduce inflammation and pain by selectively inhibiting the COX-2 enzyme, which plays a key role in the inflammatory response. Unlike nonsteroidal anti-inflammatory drugs (NSAIDs) that inhibit both COX-1 and COX-2 enzymes, COX-2 inhibitors target only the COX-2 enzyme, potentially minimizing the gastrointestinal side effects often associated with traditional NSAIDs. This selective inhibition is thought to provide effective relief from conditions like arthritis and other inflammatory disorders while reducing the risk of adverse effects such as stomach ulcers and bleeding.
Despite their benefits, COX-2 inhibitors have been associated with an increased risk of cardiovascular events, such as heart attacks and strokes. This risk is attributed to the fact that COX-2 plays a role in maintaining the balance of prostaglandins that protect the cardiovascular system. As a result, the use of COX-2 inhibitors requires careful consideration of a patient’s cardiovascular health and a balance between their therapeutic benefits and potential risks. Examples of COX-2 inhibitors include celecoxib and etoricoxib, which are commonly prescribed for managing pain and inflammation.
Find out more about cyclo-oxygenase 2 inhibitors drugs @ Cyclo-oxygenase 2 Inhibitors Analysis
A snapshot of the Pipeline Cyclo-oxygenase 2 Inhibitors Drugs mentioned in the report:
| Drugs | Company | Phase | Indication | RoA |
| AXS-07 | Axsome Therapeutics | Preregistration | Migraine | Oral |
| ALLOD-2 | Allodynic Therapeutics | Phase II/III | Back pain; Migraine | Oral |
| YIV 906 | Yiviva | Phase II | Colorectal cancer; Liver cancer | Oral |
| NOV-1776 | Novilla Pharmaceuticals | Phase I | Acute pain | Intravenous |
| STP 707 | Sirnaomics | Phase I | Solid Tumor | Intravenous |
Learn more about the emerging cyclo-oxygenase 2 inhibitors @ Cyclo-oxygenase 2 Inhibitors Clinical Trials
Cyclo-oxygenase 2 Inhibitors Therapeutics Assessment
The cyclo-oxygenase 2 inhibitors pipeline report proffers an integral view of the emerging cyclo-oxygenase 2 inhibitors segmented by stage, product type, molecule type, and route of administration.
Scope of the Cyclo-oxygenase 2 Inhibitors Pipeline Report
- Coverage: Global
- Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
- Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Therapeutics Assessment By Route of Administration: Infusion, Intradermal, Intramuscular, Intranasal, Intravaginal, Oral, Parenteral, Subcutaneous, Topical
- Therapeutics Assessment By Molecule Type: Vaccines, Monoclonal Antibody, Peptides, Polymer, Small molecule
- Key Cyclo-oxygenase 2 Inhibitors Companies: Allodynic Therapeutics, Merck & Co., Axsome Therapeutics, Novilla Pharmaceuticals, Daehwa Pharmaceutical, Holy Stone Healthcare, NeuroSense Therapeutics, Virios Therapeutics, Sound Pharmaceuticals, Sirnaomics, Yiviva, and others
- Key Cyclo-oxygenase 2 Inhibitors Pipeline Therapies: CA102N, ALLOD 2, MK 0663, AXS 07, NOV-1776, DHP-2306, PrimeC, IMC-2, SPI-1005, STP 707, YIV 906, and others
Dive deep into rich insights for new cyclo-oxygenase 2 inhibitors, visit @ Cyclo-oxygenase 2 Inhibitors Drugs
Table of Contents
| 1. | Cyclo-oxygenase 2 Inhibitors Pipeline Report Introduction |
| 2. | Cyclo-oxygenase 2 Inhibitors Pipeline Report Executive Summary |
| 3. | Cyclo-oxygenase 2 Inhibitors Pipeline: Overview |
| 4. | Analytical Perspective In-depth Commercial Assessment |
| 5. | Cyclo-oxygenase 2 Inhibitors Clinical Trial Therapeutics |
| 6. | Cyclo-oxygenase 2 Inhibitors Pipeline: Late-Stage Products (Pre-registration) |
| 7. | Cyclo-oxygenase 2 Inhibitors Pipeline: Late-Stage Products (Phase III) |
| 8. | Cyclo-oxygenase 2 Inhibitors Pipeline: Mid-Stage Products (Phase II) |
| 9. | Cyclo-oxygenase 2 Inhibitors Pipeline: Early-Stage Products (Phase I) |
| 10. | Cyclo-oxygenase 2 Inhibitors Pipeline Therapeutics Assessment |
| 11. | Inactive Products in the Cyclo-oxygenase 2 Inhibitors Pipeline |
| 12. | Company-University Collaborations (Licensing/Partnering) Analysis |
| 13. | Key Companies |
| 14. | Key Products in the Cyclo-oxygenase 2 Inhibitors Pipeline |
| 15. | Unmet Needs |
| 16. | Market Drivers and Barriers |
| 17. | Future Perspectives and Conclusion |
| 18. | Analyst Views |
| 19. | Appendix |
For further information on the cyclo-oxygenase 2 inhibitors pipeline therapeutics, reach out @ Cyclo-oxygenase 2 Inhibitors Therapeutics
Related Reports
Migraine Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key migraine companies, including Lundbeck Seattle BioPharmaceutical, Eli Lilly and Company, Amgen, Novartis, Teva Pharmaceuticals, Allergan, Biohaven Pharmaceuticals, Dr. Reddy’s Labs, AbbVie, Impel NeuroPharma, Zosano Pharma, Axsome Therapeutics, Aeon Biopharma Inc., Ionis Pharmaceuticals, Inc., Charleston Laboratories, among others.
Migraine Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key migraine companies, including Satsuma Pharmaceuticals, Biohaven Pharmaceuticals, Allodynic Therapeutics, Vaxxinity, AbbVie, Pulmatrix, AEON Biopharma, Eli Lilly and Company, Trevena, Xoc Pharmaceuticals, Pharmaleads, Pear Therapeutics, among others.
Chronic Lower Back Pain Market
Chronic Lower Back Pain Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key CLBP companies, including Eli Lilly and Company, Camurus, Braeburn Inc., Scilex Holding, Mesoblast Limited, AnGes MG, Inc., among others.
Chronic Lower Back Pain Pipeline
Chronic Lower Back Pain Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key chronic lower back pain companies, including Mesoblast, Eli Lilly and Company, Persica Pharmaceuticals, CHABiotech, Allodynic Therapeutics, Stayble Therapeutics, Xgene Pharmaceutical, Imbrium Therapeutics, Camurus, among others.
Chronic Back Pain Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key chronic back pain companies, including Mesoblast, Eli Lilly and Company, Persica Pharmaceuticals, CHABiotech, Allodynic Therapeutics, Stayble Therapeutics, Xgene Pharmaceutical, Imbrium Therapeutics, Camurus, among others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences.
Connect with us at LinkedIn
Contact Us Shruti Thakur info@delveinsight.com +14699457679 www.delveinsight.com
© Copyright Globe Newswire, Inc. All rights reserved. The information contained in this news report may not be published, broadcast or otherwise distributed without the prior written authority of Globe Newswire, Inc.
